Printer Friendly

ALPHA 1 BIOMEDICALS, INC. FOURTH QUARTER AND CALENDAR YEAR 1992 RESULTS

 BETHESDA, Md., March 26 /PRNewswire/ -- Alpha 1 Biomedicals, Inc. (NASDAQ: ALBM) today reported financial results for the fourth quarter and year ended Dec. 31, 1992.
 Revenues for the fourth quarter were $63,281 and expenses were $1,081,310 resulting in a net loss of $1,018,029 or $.14 per share. The results for the same quarter of the preceding year were $579,517 in revenues, $829,607 in expenses and a loss of $250,090 or $.03 per share.
 For the year, revenues of $222,385 and expenses of $4,385,091 resulted in a loss of $4,162,706 or $.57 per share. The results for 1991 were revenues of $707,353 and expenses of $3,206,423 for a loss of $2,499,070 or $.38 per share. Fourth quarter and full year 1991 revenue reflect the recognition of $466,667 from a licensing agreement.
 Reported losses for the quarter and year were in line with management's expectations and the increases from the prior periods were the result of the combination of the recording of licensing revenue in the prior periods and increased current period expenses of ongoing clinical trials and operating costs.
 Earlier this month the company received proceeds of nearly $11 million, and issued approximately 1.1 million common shares and Class C Warrants in connection with the exercise of its Class B Warrants. Proceeds received from the exercise will be used for general corporate purposes including the addition of staff, initiation of additional clinical trials and to increase the company's manufacturing capacity.
 Alpha 1 Biomedicals, Inc. a Bethesda, MD-based company is engaged in the development of pharmaceutical products for the treatment of chronic viral diseases, immune disorders and cancer. The company's lead drug, Thymosin alpha 1, is currently in U.S. clinical trials for the treatment of chronic hepatitis B, chronic hepatitis C and AIDS.
 ALPHA 1 BIOMEDICALS, INC.
 Statements of Operations
 Three months ended Year ended
 12/31/92 12/31/91 12/31/92 12/31/91
 (Unaudited)
 Revenue $63,281 $579,517 $222,385 $707,353
 Expenses 1,081,311 829,607 4,385,091 3,206,423
 Net loss 1,018,030 250,090 4,162,706 2,499,070
 Net loss per
 common share .14 .03 .57 .38
 Weighted average
 common shares
 outstanding 7,327,200 7,238,509 7,317,428 6,512,903
 -0- 3/26/93
 /CONTACT: R.J. Lanham, vice president finance & administration, of Alpha 1 Biomedicals, Inc., 301-564-4400, or Anita Monteith-Dixon of Long Ridge Associates, 203-790-0647, for Alpha 1 Biomedicals/
 (ALBM)


CO: Alpha 1 Biomedicals, Inc. ST: Maryland IN: MTC SU: ERN

LD-KW -- NY051 -- 0210 03/26/93 18:13 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 26, 1993
Words:448
Previous Article:DANIELSON HOLDING ACQUIRES HOMEFED TRUST COMPANY
Next Article:INTERMARK INC. AND TRITON GROUP LTD. DISCLOSURE STATEMENT APPROVED
Topics:


Related Articles
ALPHA 1 BIOMEDICALS, INC. REPORTS THIRD QUARTER CALENDAR YEAR 1992 RESULTS
U.S. TESTS OF POTENTIAL AIDS VACCINE CONFIRM EARLIER U.K. TESTS
ALPHA 1 BIOMEDICALS ANNOUNCES REVISIONS TO TERMS OF THE REDEMPTION OF ITS CLASS B WARRANTS
ALPHA 1 BIOMEDICALS INC. ANNOUNCES MANUFACTURING EXPANSION
ALPHA 1 BIOMEDICALS, INC. ANNOUNCES PUBLICATION OF PRICE APPROVAL OF THYMOSIN ALPHA 1 IN ITALY
ENROLLMENT COMPLETED IN ALPHA 1 BIOMEDICALS' PHASE III CLINICAL TRIAL
UPDATE ON HGP-30 AIDS VACCINE PRESENTED AT BERLIN AIDS CONFERENCE
ALPHA 1 BIOMEDICALS, INC. APPOINTS SUZANNE K. BECKNER AS DIRECTOR OF DEVELOPMENT
THYMOSIN ALPHA 1 COMBINATION STUDY SUGGESTS CD4+ RESPONSE
ICN BIOMEDICALS REPORTS FIRST QUARTER EARNINGS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters